$6.78
4.44% today
Nasdaq, Nov 20, 08:49 pm CET
ISIN
US82835W1080
Symbol
SPRY

Silverback Therapeutics Stock price

$7.09
-2.92 29.17% 1M
-7.17 50.28% 6M
-3.46 32.80% YTD
-6.70 48.59% 1Y
+0.81 12.90% 3Y
-13.91 66.24% 5Y
-13.91 66.24% 10Y
-13.91 66.24% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.01 0.07%
ISIN
US82835W1080
Symbol
SPRY
Industry

Key metrics

Basic
Market capitalization
$700.8m
Enterprise Value
$508.9m
Net debt
positive
Cash
$288.2m
Shares outstanding
98.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.9 | 8.5
EV/Sales
3.6 | 6.2
EV/FCF
negative
P/B
4.8
Financial Health
Equity Ratio
73.1%
Return on Equity
3.1%
ROCE
-28.2%
ROIC
-
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$142.8m | $82.3m
EBITDA
$-89.8m | $-150.2m
EBIT
$-90.8m | $-176.1m
Net Income
$-80.0m | $-166.2m
Free Cash Flow
$-86.0m
Growth (TTM | estimate)
Revenue
5,455.3% | -7.7%
EBITDA
-48.6% | -4,941.5%
EBIT
-50.0% | -5,617.2%
Net Income
-63.0% | -2,176.9%
Free Cash Flow
-86.9%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-62.9% | -182.5%
EBIT
-63.6%
Net
-56.1% | -201.8%
Free Cash Flow
-60.3%
More
EPS
$-0.8
FCF per Share
$-0.9
Short interest
32.6%
Employees
165
Rev per Employee
$540.0k
Show more

Is Silverback Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Silverback Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Silverback Therapeutics forecast:

Buy
92%
Hold
8%

Financial data from Silverback Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
143 143
5,455% 5,455%
100%
- Direct Costs 15 15
13,655% 13,655%
11%
128 128
6,412% 6,412%
89%
- Selling and Administrative Expenses 206 206
378% 378%
144%
- Research and Development Expense 13 13
36% 36%
9%
-90 -90
49% 49%
-63%
- Depreciation and Amortization 0.98 0.98
1,533% 1,533%
1%
EBIT (Operating Income) EBIT -91 -91
50% 50%
-64%
Net Profit -80 -80
63% 63%
-56%

In millions USD.

Don't miss a Thing! We will send you all news about Silverback Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Silverback Therapeutics Stock News

Neutral
Seeking Alpha
10 days ago
ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, President, CEO & Director Eric Karas - Chief Commercial Officer Kathleen Scott - Chief Financial Officer Conference Call Participants Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Joshua Sch...
Positive
Seeking Alpha
10 days ago
ARS Pharmaceuticals, Inc. delivered strong Q3 Neffy sales, doubling sequentially, but remains unprofitable with high SG&A expenses and no 2026 guidance. SPRY faces competitive threats from generics and upcoming alternatives, but patent litigation could delay generic Neffy entry until 2039. Neffy's needle-free, lower-cost profile is driving adoption, with growing prescriber base and internationa...
Neutral
GlobeNewsWire
10 days ago
$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025
More Silverback Therapeutics News

Company Profile

Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson on January 4, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Richard Lowenthal
Employees 165
Founded 2015
Website ars-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today